Targeting the myostatin pathway potentially offers an approach for treating cancer as well as age-, obesity-, and spinal dystrophy-related muscle loss associated with progressive body wasting and loss of motor function [162] (Table 6). The gene discussed is MSTN; the disease is obesity due to melanocortin 4 receptor deficiency.